PATENT COOPERATION TREATY

From the NTERNATIONAL PRELIMINARY EXA	MINING AUTHORITY					9
To: GAL EHRLICH C/O ANTHONY CASTORINA			PCT	REC'D	13 FE	B 2008
2001 JEFFERSON DAVIS HIGHWAY SUITE 207			WRITTEN OPIN	WIPO		F
ARLINGTON, VA 22202			(PCT Rule 66			
		Date of Mailing (day/month/year)	08 FFR	0000		
Applicant's or agent's file reference		REPLY DUE		2006		
01/22967			within 1 months/days the above date of mail	ling		
International application No.	International filing date	(day/month/year)	Priority date (day/me	onth/year)		
PCT/IL01/01169	17 December 2001 (17.	12.2001)	19 December 2000 (19.12.2000		
International Patent Classification (IPC)						
IPC(7): A01N 63/00; A61K 48/00; C12N 372	5/00, 5/08, 15/63, 15/85	and US Cl.: 424/93.1,	93.21, 93.7; 435/455,	, 320.1, 325	, 363, 366 ———	·,
Applicant INSIGHT STRATEGY AND MARKETI	NG LTD.					
IV Lack of unity of in V Reasoned stateme citations and explain the component of the compo	ons relating to the follow on at of opinion with regard to invention and under Rule 66.2 (a)(ii) anations supporting such as cited the international applications on the international applications	o novelty, inventive so with regard to novelty statement ion oplication	tep and industrial appl	licability	licability;	
3. The applicant is hereby invite When? See the time?	ed to reply to this opinion limit indicated above. Th		re the expiration of the	at-time limit	, request	this
Authority to a	grant an extension. See r u	lo 66.2(d).				
For the form	g a written reply, accomp and the language of the a	mendments, see Rules	66.8 and 66.9.	iccording to	Kule oo.,	3.
For the exam For an inform	onal opportunity to submi iner's obligation to considual communication with t	der amendments and/o he examiner, see Rule	r arguments, see Rule 66.6			
If no reply is filed, the interr		ination report will be	established on the bas	sis of this op	inion.	
The final date by which the in examination report must be examination.		ule 69.2 is: <u>19 April 2</u>		<i>·</i> :	/	
Name and mailing address of the IPEA	/US	Authorizad office	r 12 11/1	eno d		
Mail Stop PCT, Atm: IPEA/ US Commissioner for Patents P.O. Box 1450	(Juang Nguyen, I	Ph.D. Juy	57		
Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201		Telephone No. (571) 272-1600	= LI		

Form PCT/IPEA/408 (cover sheet)(July 1998)

International	application	No.

PCT/IL01/01169

Basis	s of the opinion
With	regard to the elements of the international application:*
	the international application as originally filed the description: pages 1-44, as originally filed pages NONE, filed with the demand pages NONE, filed with the letter of
\boxtimes	the claims: pages 45-60, as originally filed pages NONE, as amended (together with any statement) under Article 19 pages NONE, filed with the demand pages NONE, filed with the letter of
	the drawings: pages 1-4, as originally filed pages NONE, filed with the demand pages NONE, filed with the letter of
\boxtimes	the sequence listing part of the description: pages 1, as originally filed pages NONE, filed with the demand pages NONE, filed with the letter of
lang The	h regard to the language, all the elements marked above were available or furnished to this Authority in the guage in which the international application was filed, unless otherwise indicated under this item. see elements were available or furnished to this Authority in the following language which is: the language of a translation furnished for the purposes of international search (under Rule23.1(b)). the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination(under Rules 55.2 and/or 55.3).
	h regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written alion was drawn on the basis of the sequence listing: contained in the international application in printed form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
-	The amendments have resulted in the cancellation of: the description, pages NONE the claims, Nos. NONE the drawings, sheets/fig NONE This opinion has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)). Indeement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in mion as "originally filed."
	With Signature With S

International application No.

PCT/IL01/01169

1. The question whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to			
1. The question whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:			
the entire international application,			
Claims Nos. <u>29-132</u>			
because:			
the said international application, or the said claim Nos relate to the following subject matter which does not require international preliminary examination (specify):			
the description, claims or drawings (indicate particular elements below) or said claims Nos are so uncleat that no meaningful opinion could be formed (specify):	r		
the claims, or said claims Nos are so inadequately supported by the description that no meaningful opinion could be formed.			
no international search report has been established for said claims Nos. 1-132.			
2. A written opinion cannot be drawn due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:	vith		
the written form has not been furnished or does not comply with the standard.			
the computer readable form has not been furnished or does not comply with the standard.			

International application No. PCT/IL01/01169

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
1. STATEMENT			
Novelty (N)	Claims	1-28	YES
		NONE	NO
	. .	1.00	VEC
Inventive Step (IS)	Claims	1-28 NONE	YES NO
		NONE	
Industrial Applicability (IA)	Claims	1-28	YES
	Claims	NONE	NO
transplantation using the same.			

Form PCT/IPEA/408 (Box V) (July 1998)

International application No.

PCT/IL01/01169

VIII. Certain observations on the international application

The following observations on the claims of the claims, description, and drawings or on the questions whether the claims are fully supported by the description, are made:

Claims 1-28 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because of the claims are not fully supported by the description. The description does not disclose the claimed invention in a manner sufficiently clear and complete for the claimed invention to be carried out by a person skilled in the art for the following reasons.

The instant claims encompass a stem cell preparation comprising stem cells coated and/or transfected with any exogenous extracellular matrix degrading enzyme, and a method of improving stem cell transplantation using the same. However, apart from the disclosure that human blood cord stem cells coating with heparanase improve transplantation in the NOD-SCID mouse model as reflected by the % of cells in the mouse bone marrow that express human CD45 and/or CD15 compared with the uncoated human blood cord stem cells, the instant application fails to provide sufficient guidance for a skilled artisan on how to obtain similar results using a stem cell preparation coating with any other exogenous extracellular matrix degrading enzymes (e.g., collagenase, elastase, trypsin, pepsin, cathepsins). It is also unclear whether the same effects could be obtained using a stem cell preparation transfected with a nucleic acid encoding for any exogenous extracellular matrix degrading enzyme, particularly whether the expression of an exogenous extracellular matrix degrading enzyme has any effect on the viability, proliferation and/or differentiation potentials of the transfected stem cells, and therefore the desired end-results contemplated by Applicants. Physiological art is recognized to be unpredictable. Therefore, with the lack of sufficient guidance provided by the instant disclosure, it would have required undue experimentation for a skilled artisan to make and use the present broadly claimed invention.

Form PCT/IPEA/408 (Box VIII) (July 1998)

WRI	TTFN	OPD	MOIN

International application No. PCT/IL01/01169

(To be used when the space in any of the preceding boxes is not sufficient)	
 TIME LIMIT: The time limit set for response to a Written Opinion may not be extended. 37 CFR 1.484(d). Any response received after the expiration of the time limit set in the Written Opinion will not be considered in preparing the International Preliminary Examination Report.	
-	

Form PCT/IPEA/408 (Supplemental Box) (July 1998)